Publication
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (22)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 22
- cancerAcute Myeloid Leukemiacivic_curation1.00
- drugAG1295civic_curation1.00
- drugAGS324civic_curation1.00
- drugCrenolanibcivic_curation1.00
- drugFLT3 Tyrosine Kinase Inhibitor TTT-3002civic_curation1.00
- drugKW2449civic_curation1.00
- drugLestaurtinibcivic_curation1.00
- drugLinifanibcivic_curation1.00
- drugMidostaurincivic_curation1.00
- drugPonatinibcivic_curation1.00
- drugQuizartinibcivic_curation1.00
- drugR406civic_curation1.00
- drugSorafenibcivic_curation1.00
- drugSunitinibcivic_curation1.00
- geneFLT3civic_curation1.00
- geneFLT3LGcivic_curation1.00
- variantFLT3 D593delcivic_curation1.00
- variantFLT3 D835Ycivic_curation1.00
- variantFLT3 I836Scivic_curation1.00
- variantFLT3 I836Tcivic_curation1.00
- variantFLT3LG Expressioncivic_curation1.00
- variantFLT3 Overexpressioncivic_curation1.00
Curated evidence
Evidence citing this paper (13)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 28077790
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FLT3 D593del2 | ||||||||
| Linifanib + Quizartinib + Sorafenib + SunitinibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 3 | submitted | EID11094A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D593del using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FL… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| Crenolanib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + Lestaurtinib + MidostaurinSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11093A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D593del using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FL… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 D835G1 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11092D835G was originally identified from an AML patient. Transfection of D835G into Ba/F3 cells led to IL3 independent growth, indicating an oncogenic driver effect for the variant in these cells. This ev… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 D835N1 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID11091D835N was originally identified from an AML patient. Transfection of D835N into Ba/F3 cells led to IL3 independent growth, indicating an oncogenic driver effect for the variant in these cells. This ev… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 D835Y4 | ||||||||
| AG1295 + AGS324 + KW2449 + Linifanib + Ponatinib + Quizartinib + R406 + Sorafenib + SunitinibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID11086A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D835Y using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FLT3… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| Lestaurtinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID11095Ba/F3 cells with FLT3 D835Y were transplanted into mice. The cells were stably transfected with luciferase and this was used to monitor disease progression with luciferin injections to visualize biolu… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| Crenolanib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + Lestaurtinib + MidostaurinSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID11085A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D835Y using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FLT3… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| Sorafenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 4 | submitted | EID11096Ba/F3 cells with FLT3 D835Y were transplanted into mice. The cells were stably transfected with luciferase and this was used to monitor disease progression with luciferin injections to visualize biolu… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 I836S1 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 2 | accepted | EID9782In this study, activating FLT3 mutations identified in patients with Acute Myeloid Leukemia were modeled using Ba/F3 cell lines generated by site-directed mutagenesis and transfection. These cells wer… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 I836T1 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | D | Supports Oncogenicity | 2 | accepted | EID9783In this study, FLT3 activating mutations identified in patients with acute myeloid leukemia were modeled using murine Ba/F3 cells generated by site-directed mutagenesis and transfection. These cells w… (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 ITD1 | ||||||||
| AG1295 + AGS324 + Crenolanib + FLT3 Tyrosine Kinase Inhibitor TTT-3002 + KW2449 + Lestaurtinib + Linifanib + Midostaurin + Ponatinib + Quizartinib + R406 + Sorafenib + SunitinibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11084A panel of FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3-ITD using MTT growth/survival assay. Each of the 13 TKIs inhibited proliferation of FLT3-ITD cells in a … (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3LG Expression + FLT3 OverexpressionFLT3LGFLT32 | ||||||||
| AG1295 + Crenolanib + R406Substitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID11089In some cancers such as infant ALL, B-lineage ALL and AML samples with the highest levels of wild-type FLT3, constitutive FLT3 phosphorylation is seen from paracrine or autocrine activation from FLT3 … (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 + KW2449 + Lestaurtinib + Linifanib + Midostaurin + Ponatinib + Quizartinib + SunitinibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID11088In some cancers such as infant ALL, B-lineage ALL and AML samples with the highest levels of wild-type FLT3, constitutive FLT3 phosphorylation is seen from paracrine or autocrine activation from FLT3 … (full text at CIViC) PMID 28077790 · Nguyen et al., 2017 · Open in CIViC | civic |